CHANNING HALL: Open Payments
NPI 1104464445 · CONWAY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,190 in 46 payments from 9 companies in 2025. Trend: 2023 $625 · 2024 $274 · 2025 $1,190
Food & beverage: $1,190
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $394 |
| Neurocrine BioSciences, Inc. | 7 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $161 |
| Vanda Pharmaceuticals Inc. | 5 | $99 |
| Lundbeck LLC | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Janssen Pharmaceuticals, Inc | 2 | $41 |
| Biogen, Inc. | 1 | $16 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, TRINTELLIX, REXULTI, FANAPT, INVEGA SUSTENNA, ZURZUVAE.
Industry payments across AR — which companies pay providers there.
